Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386435 | 0.95 | PTGS2 (0.40) | PTGS2CSNK1DCSNK1EPTGS1MAPK14 | |
| SCHEMBL29652671 | 0.92 | PTGS2 (0.38) | PTGS2CSNK1DCSNK1EPTGS1MAPK14 | |
| SCHEMBL1384763 | 0.86 | MAP4K4 (0.42) | PTGS2CSNK1DCSNK1EPTGS1MAPK14 | |
| SCHEMBL31213167 | 0.85 | PTGS2 (0.42) | PTGS2PTGS1MAPK14KDM4EMITF | |
| SCHEMBL1387131 | 0.83 | MAPK14 (0.46) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL1385020 | 0.80 | KMO (0.36) | PTGS2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1385005 | 0.78 | MAPK14 (0.44) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL1386713 | 0.78 | PTGS2 (0.38) | PTGS2CSNK1DCSNK1EPTGS1MAPK14 | |
| SCHEMBL1387079 | 0.77 | PRKD3 (0.49) | CSNK1DMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1385236 | 0.75 | MAPK14 (0.43) | CSNK1DCSNK1EMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | claimed |
| JP-4814783-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | claimed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| EP-1611131-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach y Compagnia S.A. (ES) | 2006-01-04 | — | — | EP | claimed |
| WO-2004076450-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach Y Compañia S.A. (ES) | 2004-09-10 | — | — | WO | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | PTGS2 1065/4885CSNK1D 75/4885CSNK1E 235/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | PTGS2 1021/4885CSNK1D 60/4885CSNK1E 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.